



18 October 2022

Re: EudraCT Results Posting for 2018-002405-64

Sponsor: Catalyst Pharmaceuticals, Inc

Sponsor Code: CMS-002

Study Title: Long Term Safety Study of Amifampridine Phosphate in Patients with Congenital Myasthenic Syndromes (CMS)

The above listed trial was never started and no patients enrolled, therefore no results of the trial are available.

A handwritten signature in blue ink, appearing to read "Gary Ingenito". The signature is fluid and cursive, with a prominent initial "G".

Gary Ingenito, MD, PhD
Chief Medical and Regulatory Officer
Catalyst Pharmaceuticals, Inc.
Email: gingenito@catalystpharma.com